Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2005 2
2006 6
2007 6
2008 8
2009 3
2010 4
2011 5
2012 13
2013 8
2014 13
2015 7
2016 12
2017 10
2018 21
2019 26
2020 28
2021 41
2022 34
2023 38
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

259 results

Results by year

Filters applied: . Clear all
Page 1
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis.
Simpson EL, de Bruin-Weller M, Hong HC, Staumont-Sallé D, Blauvelt A, Eyerich K, Gooderham M, Shahriari M, Mallbris L, Atwater AR, Rueda MJ, Ding Y, Liu Z, Agell H, Silverberg JI. Simpson EL, et al. Dermatol Ther (Heidelb). 2024 May 3. doi: 10.1007/s13555-024-01158-4. Online ahead of print. Dermatol Ther (Heidelb). 2024. PMID: 38700646
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies.
Eichenfield LF, Simpson EL, Papp K, Szepietowski JC, Blauvelt A, Kircik L, Silverberg JI, Siegfried EC, Kuligowski ME, Venturanza ME, Kallender H, Ren H, Paller AS. Eichenfield LF, et al. Among authors: simpson el. Am J Clin Dermatol. 2024 May 2. doi: 10.1007/s40257-024-00855-2. Online ahead of print. Am J Clin Dermatol. 2024. PMID: 38698175
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).
Simpson EL, Prajapati VH, Leshem YA, Chovatiya R, de Bruin-Weller MS, Ständer S, Pink AE, Calimlim BM, Lee WJ, Teixeira H, Ladizinski B, Hu X, Yang Y, Liu Y, Liu M, Grada A, Platt AM, Silverberg JI. Simpson EL, et al. Dermatol Ther (Heidelb). 2024 May 2. doi: 10.1007/s13555-024-01157-5. Online ahead of print. Dermatol Ther (Heidelb). 2024. PMID: 38696027
Evaluating the clinical utility of the Atopic Dermatitis Control Tool: measurement properties and agreement between patients' responses and clinicians' impressions of atopic dermatitis control.
Simpson EL, Eckert L, Gadkari A, Brown TM, Lio PA, Lockshin B, Nelson L, Fehnel SE, Mahajan P, Chao J, Nygårdas M, Guillemin I. Simpson EL, et al. Br J Dermatol. 2024 Apr 9:ljae056. doi: 10.1093/bjd/ljae056. Online ahead of print. Br J Dermatol. 2024. PMID: 38593196 No abstract available.
Characterization of disease burden, treatment and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis Registry.
Silverberg JI, Cronin A, Jones EA, Dave SS, McLean RR, Greenberg J, Strober B, Bieber T, Gooderham M, Paller AS, Simpson EL. Silverberg JI, et al. Among authors: simpson el. JAAD Int. 2024 Feb 12;15:127-130. doi: 10.1016/j.jdin.2023.11.015. eCollection 2024 Jun. JAAD Int. 2024. PMID: 38545488 Free PMC article. No abstract available.
Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies.
Simpson EL, Bissonnette R, Chiesa Fuxench ZC, Kallender H, Sturm D, Ren H, Stein Gold LF. Simpson EL, et al. J Dermatolog Treat. 2024 Dec;35(1):2310633. doi: 10.1080/09546634.2024.2310633. Epub 2024 Jan 31. J Dermatolog Treat. 2024. PMID: 38297490 Free article.
Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial.
Simpson EL, Silverberg JI, Worm M, Honari G, Masuda K, Syguła E, Schuttelaar MLA, Mortensen E, Laws E, Akinlade B, Patel N, Maloney J, Paleczny H, Delevry D, Xiao J, Dubost-Brama A, Bansal A. Simpson EL, et al. J Am Acad Dermatol. 2024 Feb 1:S0190-9622(24)00146-4. doi: 10.1016/j.jaad.2023.12.066. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 38296199 Free article.
Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b Study.
Guttman-Yassky E, Simpson EL, Reich K, Kabashima K, Igawa K, Suzuki T, Mano H, Matsui T, Esfandiari E, Furue M. Guttman-Yassky E, et al. Among authors: simpson el. Adv Ther. 2024 Mar;41(3):928-931. doi: 10.1007/s12325-023-02755-z. Epub 2024 Jan 8. Adv Ther. 2024. PMID: 38185777 Free PMC article. Clinical Trial.
259 results